Châtillon, France, June 03, 2025
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
Read more at globenewswire.com